{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:17:21Z","timestamp":1773307041535,"version":"3.50.1"},"reference-count":69,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MINECO","award":["SAF2012-30862;"],"award-info":[{"award-number":["SAF2012-30862;"]}]},{"name":"MINECO","award":["SAF2015-64215R"],"award-info":[{"award-number":["SAF2015-64215R"]}]},{"name":"Fundacion leticia Castilejo Castillo"},{"name":"European Comunity trough the Regional Development Funding Program"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0200878","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T18:12:20Z","timestamp":1532628740000},"page":"e0200878","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1\/2 independent fashion"],"prefix":"10.1371","volume":"13","author":[{"given":"Leticia","family":"Serrano-Oviedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ortega-Muelas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8312-2622","authenticated-orcid":true,"given":"Jes\u00fas","family":"Garc\u00eda-Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Ll.","family":"Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Cimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Pascual-Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego M.","family":"Fernandez-Aroca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"Ruiz-Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borja","family":"Belandia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-8813","authenticated-orcid":true,"given":"Jos\u00e9 M.","family":"Gim\u00e9nez-Bachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1837-6981","authenticated-orcid":true,"given":"Antonio S.","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0882-9780","authenticated-orcid":true,"given":"Ricardo","family":"Sanchez-Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"BJ Druker","year":"1996","journal-title":"Nat Med"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"PTC Wan","year":"2004","journal-title":"Cell"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bcp.2010.03.019","article-title":"BRAF as therapeutic target in melanoma","volume":"80","author":"C Wellbrock","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"19","key":"ref4","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"SM Wilhelm","year":"2004","journal-title":"Cancer Res"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2217\/fon.15.85","article-title":"Sorafenib: 10 years after the first pivotal trial","volume":"11","author":"G Gadaleta-Caldarola","year":"2015","journal-title":"Future Oncol Lond Engl"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"C Shen","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"ref7","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"DB Mendel","year":"2003","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/cam4.302","article-title":"Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries","volume":"3","author":"C Porta","year":"2014","journal-title":"Cancer Med"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","article-title":"Pathological roles of MAPK signaling pathways in human diseases","volume":"1802","author":"EK Kim","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2174\/092986712799320510","article-title":"RAS\/RAF\/MEK inhibitors in oncology","volume":"19","author":"P Rusconi","year":"2012","journal-title":"Curr Med Chem"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/0008-5472.CAN-13-2381","article-title":"ERKs in cancer: friends or foes?","volume":"74","author":"X Desch\u00eanes-Simard","year":"2014","journal-title":"Cancer Res"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1371\/journal.pone.0006124","article-title":"ERK2, but not ERK1, mediates acquired and \u2018de novo\u2019 resistance to imatinib mesylate: implication for CML therapy","volume":"4","author":"CI Aceves-Luquero","year":"2009","journal-title":"PloS One"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/0008-5472.CAN-12-4721","article-title":"ERK1\/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition","volume":"74","author":"JM Buonato","year":"2014","journal-title":"Cancer Res"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","article-title":"Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors","volume":"2","author":"D Ercan","year":"2012","journal-title":"Cancer Discov"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"E898","DOI":"10.1210\/jc.2011-3269","article-title":"Activation of the RAS\/RAF\/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines","volume":"97","author":"A Piscazzi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1741-7015-7-41","article-title":"Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study","volume":"7","author":"Z Zhang","year":"2009","journal-title":"BMC Med"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.0.CO;2-S","article-title":"MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor","volume":"178","author":"Y Yu","year":"1999","journal-title":"J Cell Physiol"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1006\/bbrc.1999.0227","article-title":"VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases","volume":"255","author":"AM Doanes","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1386-6346(03)00112-8","article-title":"ERK\/MAPK-dependent PI3K\/Akt phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cells","volume":"26","author":"M Takahashi","year":"2003","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"E211","DOI":"10.1111\/j.1464-410X.2012.11655.x","article-title":"Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation","volume":"112","author":"I Sakai","year":"2013","journal-title":"BJU Int"},{"issue":"9","key":"ref21","first-page":"801","article-title":"Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model","volume":"16","author":"K Harada","year":"2014","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"issue":"17","key":"ref22","doi-asserted-by":"crossref","first-page":"15551","DOI":"10.18632\/oncotarget.3902","article-title":"Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance","volume":"6","author":"J Garc\u00eda-Cano","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4161\/cc.26754","article-title":"E1a promotes c-Myc-dependent replicative stress: implications in glioblastoma radiosensitization","volume":"13","author":"ML Valero","year":"2014","journal-title":"Cell Cycle Georget Tex"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1593\/neo.121896","article-title":"ERK5\/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma","volume":"15","author":"L Arias-Gonz\u00e1lez","year":"2013","journal-title":"Neoplasia N Y N"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.3392","article-title":"Tumor adaptation and resistance to RAF inhibitors","volume":"19","author":"P Lito","year":"2013","journal-title":"Nat Med"},{"issue":"29","key":"ref26","doi-asserted-by":"crossref","first-page":"18623","DOI":"10.1074\/jbc.273.29.18623","article-title":"Identification of a novel inhibitor of mitogen-activated protein kinase kinase","volume":"273","author":"MF Favata","year":"1998","journal-title":"J Biol Chem"},{"issue":"23","key":"ref27","doi-asserted-by":"crossref","first-page":"13585","DOI":"10.1074\/jbc.270.23.13585","article-title":"Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor","volume":"270","author":"L Pang","year":"1995","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"ref28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-5793(01)02651-5","article-title":"Effects of MAP kinase cascade inhibitors on the MKK5\/ERK5 pathway","volume":"502","author":"N Mody","year":"2001","journal-title":"FEBS Lett"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0014-5793(95)00357-F","article-title":"SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1","volume":"364","author":"A Cuenda","year":"1995","journal-title":"FEBS Lett"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/ERC-11-0298","article-title":"Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways","volume":"19","author":"SJ Oh","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo","volume":"9","author":"H Hirai","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)","volume":"12","author":"DJ Klionsky","year":"2016","journal-title":"Autophagy"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1073\/pnas.79.6.1889","article-title":"3-Methyladenine: specific inhibitor of autophagic\/lysosomal protein degradation in isolated rat hepatocytes","volume":"79","author":"PO Seglen","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1091\/mbc.11.3.969","article-title":"Apg5p functions in the sequestration step in the cytoplasm-to-vacuole targeting and macroautophagy pathways","volume":"11","author":"MD George","year":"2000","journal-title":"Mol Biol Cell"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/bjc.2011.55","article-title":"Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model","volume":"104","author":"JSP Yuen","year":"2011","journal-title":"Br J Cancer"},{"issue":"18 Pt 2","key":"ref36","doi-asserted-by":"crossref","first-page":"6388S","DOI":"10.1158\/1078-0432.CCR-040028","article-title":"Kinase inhibition with BAY 43\u20139006 in renal cell carcinoma","volume":"10","author":"T Ahmad","year":"2004","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43\u20139006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"YS Chang","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/hep.25872","article-title":"Cyclic AMP\/PKA-dependent paradoxical activation of Raf\/MEK\/ERK signaling in polycystin-2 defective mice treated with sorafenib","volume":"56","author":"C Spirli","year":"2012","journal-title":"Hepatol Baltim Md"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3892\/mmr.2013.1782","article-title":"Stimulatory effects of sorafenib on human non-small cell lung cancer cells in vitro by regulating MAPK\/ERK activation","volume":"9","author":"Y-N Zhang","year":"2014","journal-title":"Mol Med Rep"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.3109\/10428194.2014.1003055","article-title":"Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation","volume":"56","author":"F Fouladi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"ref41","article-title":"Sorafenib paradoxically activates the RAS\/RAF\/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner","author":"J Lohmeyer","year":"2018","journal-title":"Clin Exp Immunol"},{"issue":"7287","key":"ref42","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"G Hatzivassiliou","year":"2010","journal-title":"Nature"},{"issue":"12","key":"ref43","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","article-title":"Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma","volume":"68","author":"C Montagut","year":"2008","journal-title":"Cancer Res"},{"issue":"7326","key":"ref44","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"CM Johannessen","year":"2010","journal-title":"Nature"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1517\/14740338.2014.892578","article-title":"Prospects for MEK inhibitors for treating cancer","volume":"13","author":"J Martin-Liberal","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3892\/ijo.2012.1494","article-title":"Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma","volume":"41","author":"JSP Yuen","year":"2012","journal-title":"Int J Oncol"},{"issue":"8","key":"ref47","first-page":"2104","article-title":"U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways","volume":"60","author":"H Fukazawa","year":"2000","journal-title":"Cancer Res"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nm.3679","article-title":"In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer","volume":"20","author":"R Rudalska","year":"2014","journal-title":"Nat Med"},{"issue":"7","key":"ref49","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/jso.21661","article-title":"Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF\/ERK\/MEK pathway","volume":"102","author":"X Lu","year":"2010","journal-title":"J Surg Oncol"},{"issue":"24","key":"ref50","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.4161\/cbt.8.24.10824","article-title":"Sorafenib inhibits ERK1\/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma","volume":"8","author":"SI Katz","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"20","key":"ref51","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1158\/0008-5472.CAN-12-0658","article-title":"Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model","volume":"72","author":"P Kharaziha","year":"2012","journal-title":"Cancer Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2119\/molmed.2011.00164","article-title":"Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1)","volume":"18","author":"J-F Fecteau","year":"2012","journal-title":"Mol Med Camb Mass"},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1078-0432.CCR-12-1935","article-title":"Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma","volume":"19","author":"S Xargay-Torrent","year":"2013","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"7","key":"ref54","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"ARD Delbridge","year":"2015","journal-title":"Cell Death Differ"},{"issue":"7","key":"ref55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.neo.2015.07.003","article-title":"Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner","volume":"17","author":"I Kiprianova","year":"2015","journal-title":"Neoplasia N Y N"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.critrevonc.2016.02.006","article-title":"The role and mechanism of autophagy in sorafenib targeted cancer therapy","volume":"100","author":"Y Heqing","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fphar.2016.00151","article-title":"Modulation of Autophagy by Sorafenib: Effects on Treatment Response","volume":"7","author":"N Prieto-Dom\u00ednguez","year":"2016","journal-title":"Front Pharmacol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1038\/cddis.2013.18","article-title":"Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells","volume":"4","author":"W-T Tai","year":"2013","journal-title":"Cell Death Dis"},{"issue":"2","key":"ref59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.intimp.2013.01.006","article-title":"Sorafenib induces autophagy and suppresses activation of human macrophage","volume":"15","author":"J-C Lin","year":"2013","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"ref60","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1078-0432.CCR-12-2293","article-title":"The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models","volume":"19","author":"Y Pignochino","year":"2013","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"ref61","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/carcin\/bgy038","article-title":"Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras\/MEK\/ERK and PI3K\/Akt\/mTOR pathways","volume":"39","author":"L Rosenberg","year":"2018","journal-title":"Carcinogenesis"},{"issue":"10","key":"ref62","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.4161\/auto.7.10.16818","article-title":"Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis","volume":"7","author":"Y-H Shi","year":"2011","journal-title":"Autophagy"},{"issue":"7","key":"ref63","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10571-015-0318-z","article-title":"Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma","volume":"36","author":"X Liu","year":"2016","journal-title":"Cell Mol Neurobiol"},{"issue":"6","key":"ref64","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-13-1043","article-title":"Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma","volume":"13","author":"B Zhai","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"ref65","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1158\/0008-5472.CAN-13-2966","article-title":"The four faces of autophagy: implications for cancer therapy","volume":"74","author":"DA Gewirtz","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"ref66","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/15384047.2015.1018494","article-title":"Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells","volume":"16","author":"A Grimaldi","year":"2015","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"ref67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PPO.0b013e31829d5cea","article-title":"Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma","volume":"19","author":"D Cho","year":"2013","journal-title":"Cancer J Sudbury Mass"},{"issue":"3","key":"ref68","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s13577-015-0112-8","article-title":"Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo","volume":"28","author":"H Tei","year":"2015","journal-title":"Hum Cell"},{"issue":"7","key":"ref69","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/0008-5472.CAN-10-2889","article-title":"eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206","volume":"71","author":"Y Cheng","year":"2011","journal-title":"Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0200878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T01:59:05Z","timestamp":1751767145000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0200878"}},"subtitle":[],"editor":[{"given":"Vladimir","family":"Trajkovic","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":69,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0200878","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]}}}